

**Intercell AG**  
**Document according to section 75a of the Austrian Stock Exchange Act (SEA)**  
**of mandatory announcements during the fiscal year 2009**

| <b>Date</b>      | <b>Type</b>                                    | <b>Description</b>   | <b>Source</b>          |
|------------------|--|--|------------------------|
| January, 01 2009 | Corporate News announcement                    | Intercell Signs Exclusive Agreement for Marketing and Distribution of its Japanese Encephalitis Vaccine in Japan and Korea           | www.intercell.com      |
| January, 23 2009 | Corporate News announcement                    | Australian authorities (TGA) first to grant final product approval for Intercell's Vaccine to Prevent Japanese Encephalitis          | www.intercell.com      |
| January, 29 2009 | Disclosure according to section 93 subs. 2 SEA | Changes in shares of voting rights: Deutsche Bank AG reduced its share in the voting rights from more than 5 % to 4.9 %.             | www.issuerinfo.oekb.at |
| March, 02 2009   | Ad-hoc announcement                            | Announcement of Q4 and preliminary full year 2008 results  | www.intercell.com      |
| March, 06 2009   | Ad-hoc announcement                            | Intercell names Reinhard Kanderer Chief Financial Officer  | www.intercell.com      |
| March, 30 2009   | Ad-hoc announcement                            | Intercell Announces FDA Approval of IXIARO®, a Novel Vaccine to Prevent Japanese Encephalitis  | www.intercell.com      |
| March, 31 2009   | Corporate News announcement                    | Intercell Announces FDA Approval of IXIARO®, a Vaccine against Japanese Encephalitis - A Successful Collaboration with the U.S. Army | www.intercell.com      |
| April, 02 2009   | Ad-hoc announcement                            | Intercell announces European approval of new vaccine, IXIARO®, to prevent Japanese Encephalitis                                      | www.intercell.com      |
| April, 07 2009   | Ad-hoc announcement                            | Intercell AG / Intercell starts a Phase I clinical trial for a new Streptococcus pneumoniae vaccine                                  | www.intercell.com      |

| <b>Date</b>    | <b>Type</b>                 | <b>Description</b>   | <b>Source</b>     |
|----------------|-----------------------------|--|-------------------|
| April, 29 2009 | Corporate News announcement | Intercell provides update on Phase III trial for Travelers' Diarrhea Vaccine Patch   | www.intercell.com |
| April, 30 2009 | Ad-hoc announcement         | Publication of 2008 Annual Report  | www.intercell.com |
| May, 07 2009   | Corporate News announcement | Intercell AG / Intercell launches Level I ADR program in the Unites States   | www.intercell.com |
| May, 08 2009   | Ad-hoc announcement         | Intercell Executes Multi-Year Contract for Supply of IXIARO® to the United States Military   | www.intercell.com |
| May, 11 2009   | Ad-hoc announcement         | Intercell AG / Intercell AG announces Q1 2009 results and business update  | www.intercell.com |
| May, 28 2009   | Ad-hoc announcement         | Invitation for the Annual General Meeting 2009   | Wiener Zeitung    |
| May, 28 2009   | Ad-hoc announcement         | Intercell AG Announces First Subject Enrolled in a Phase II Trial for the further development of its investigational Vaccine Enhancement Patch to improve Pandemic Influenza prevention in Collaboration with U.S. Department of Health and Human Services (HHS) | www.intercell.com |
| May, 28 2009   | Corporate News announcement | Intercell AG / Report of the Management Board to the Annual Shareholders' Meeting pursuant to Section 98 (3) and Section 159 (2) (3) Stock Corporation Act   | Wiener Zeitung    |
| June, 25 2009  | Corporate News announcement | Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immunization Practices   | www.intercell.com |

| <b>Date</b>       | <b>Type</b>                                    | <b>Description</b>   | <b>Source</b>          |
|-------------------|--|--|------------------------|
| July, 21 2009     | Corporate News announcement                    | Intercell AG / Publication pursuant to Sections 4 and 5 of the Publication Ordinance 2002 INTERCELL AG, ISIN: AT0000612601 | www.intercell.com      |
| July, 31 2009     | Disclosure according to section 93 subs. 2 SEA | Announcement of new total number of voting rights  | www.issuerinfo.oekb.at |
| August, 17 2009   | Ad-hoc announcement                            | Announcement of Q2 and Half Year financial report and business update  | www.intercell.com      |
| October, 14 2009  | Ad-hoc announcement                            | Intercell starts European Pivotal Phase III clinical trial for the patch-based Travelers' Diarrhea Vaccine                 | www.intercell.com      |
| October, 30 2009  | Ad-hoc announcement                            | Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis                       | www.intercell.com      |
| November, 09 2009 | Ad-hoc announcement                            | Announcement of Q3 results and business update   | www.intercell.com      |
| November, 30 2009 | Disclosure according to section 93 subs. 2 SEA | Announcement of new total number of voting rights  | www.issuerinfo.oekb.at |
| December, 11 2009 | Ad-hoc announcement                            | Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines         | www.intercell.com      |

| <b>Date</b>       | <b>Type</b>                                    | <b>Description</b>   | <b>Source</b>          |
|-------------------|--|--|------------------------|
| December, 15 2009 | Corporate News announcement                    | Report according to 159 (2) lit 3 and sec.95 (6) and Stock Corporations Act. Report of the management board on the issuance of stock options to members of the management board and employees  | Wiener Zeitung         |
| December, 15 2009 | Corporate News announcement                    | Intercell AG/ Report according to section 171 and 153 Stock Corporation Act. Report on issuance of 0.9 million new shares of common stock at an issue price of € 31.21 per share to GlaxoSmithKline Biologicals SA and exclusion of subscription rights of existing shareholders | Wiener Zeitung         |
| December, 16 2009 | Ad-hoc announcement                            | Intercell provides update on ongoing Phase II vaccine studies  | www.intercell.com      |
| December, 28 2009 | Corporate News announcement                    | Intercell announces initiation in the U.S. of a Phase III study for vaccine to protect children against Japanese Encephalitis  | www.intercell.com      |
| December, 30 2009 | Disclosure according to section 93 subs. 2 SEA | Announcement of new total number of voting rights  | www.issuerinfo.oekb.at |